F. Mingozzi and K. A. High, Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges, Nat. Rev. Genet, vol.12, pp.341-355, 2011.

D. Wang, P. W. Tai, and G. Gao, Adeno-associated virus vector as a platform for gene therapy delivery, Nat. Rev. Drug. Discov, vol.18, pp.358-378, 2019.

L. A. George, Hemophilia B gene therapy with a high-specific-activity factor IX Variant, N. Engl. J. Med, vol.377, pp.2215-2227, 2017.

A. M. Maguire, Safety and efficacy of gene transfer for Leber's congenital amaurosis, N. Engl. J. Med, vol.358, pp.2240-2248, 2008.

C. S. Manno, Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response, Nat Med, vol.12, pp.342-347, 2006.

J. R. Mendell, Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy, N. Engl. J. Med, vol.377, pp.1713-1722, 2017.

W. Miesbach, Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B, 2017.

A. C. Nathwani, Long-term safety and efficacy of factor IX gene therapy in hemophilia B, N. Engl. J. Med, vol.371, 1994.

S. Rangarajan, AAV5-Factor VIII Gene Transfer in Severe Hemophilia A, N. Engl. J. Med, vol.377, pp.2519-2530, 2017.

S. M. Hoy, Onasemnogene Abeparvovec: First Global Approval, 2019.

S. Yla-herttuala, Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union, Mol. Ther, vol.20, pp.1831-1832, 2012.

U. Patel, M. Boucher, L. De-leseleuc, and S. Visintini, In CADTH Issues in Emerging Health Technologies, vol.1, p.11, 2016.

P. Colella, G. Ronzitti, and F. Mingozzi, Emerging Issues in AAV-Mediated In Vivo Gene Therapy, Mol. Ther. Methods Clin. Dev, vol.8, pp.87-104, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01812088

R. Calcedo, Adeno-associated virus antibody profiles in newborns, children, and adolescents, Clin Vaccine Immunol, vol.18, pp.1586-1588, 2011.

K. Erles, P. Sebokova, and J. R. Schlehofer, Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV), J Med Virol, vol.59, pp.406-411, 1999.

C. Li, Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia, Gene Ther, 2011.

E. Masat, G. Pavani, and F. Mingozzi, Humoral immunity to AAV vectors in gene therapy: challenges and potential solutions, Discov. Med, vol.15, pp.379-389, 2013.

C. Vandamme, O. Adjali, and F. Mingozzi, Unraveling the Complex Story of Immune Responses to AAV Vectors Trial After Trial. Hum, Gene Ther, vol.28, pp.1061-1074, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01798967

C. D. Scallan, Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice, Blood, vol.107, pp.1810-1817, 2006.

H. Jiang, Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy, Blood, vol.108, pp.3321-3328, 2006.

G. Bortolussi, Life-long correction of hyperbilirubinemia with a neonatal liver-specific AAV-mediated gene transfer in a lethal mouse model of Crigler-Najjar Syndrome, Hum. Gene Ther, vol.25, pp.844-855, 2014.

S. Boutin, Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum, Gene Ther, vol.21, pp.704-712, 2010.

D. Z. De-back, M. M. Neyrinck, and H. Vrielink, Therapeutic plasma apheresis: Expertise and indications, Transfus. Apher. Sci, vol.58, pp.254-257, 2019.

V. Monteilhet, A 10 Patient Case Report on the Impact of Plasmapheresis Upon Neutralizing Factors Against Adeno-associated Virus (AAV) Types 1, 2, 6, and 8, Mol. Ther, 2011.

L. Chicoine, Plasmapheresis Eliminates the Negative Impact of AAV Antibodies on Microdystrophin Gene Expression Following Vascular Delivery, Mol. Ther, 2013.

G. D. Hurlbut, Preexisting immunity and low expression in primates highlight translational challenges for liver-directed AAV8-mediated gene therapy, Mol. Ther, vol.18, 1983.

D. Salas, Immunoadsorption enables successful rAAV5-mediated repeated hepatic gene delivery in nonhuman primates, Blood Adv, vol.3, pp.2632-2641, 2019.

A. Kaplan, Complications of apheresis, Semin. Dial, vol.25, pp.152-158, 2012.

Z. Fitzpatrick, Influence of Pre-existing Anti-capsid Neutralizing and Binding Antibodies on AAV Vector Transduction, Mol. Ther. Methods Clin. Dev, vol.9, pp.119-129, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02377512

L. Wang, The pleiotropic effects of natural AAV infections on liver-directed gene transfer in macaques, Mol Ther, vol.18, pp.126-134, 2010.

S. J. Tzartos, Antigen-specific apheresis of pathogenic autoantibodies from myasthenia gravis sera, Ann. N. Y. Acad. Sci, vol.1132, pp.291-299, 2008.

L. Rydberg, A. Bengtsson, O. Samuelsson, K. Nilsson, and M. E. Breimer, In vitro assessment of a new ABO immunosorbent with synthetic carbohydrates attached to sepharose, Transpl. Int, vol.17, pp.666-672, 2005.

H. Amital, Antibodies against the VRT101 laminin epitope correlate with human SLE disease activity and can be removed by extracorporeal immunoadsorption, Rheumatol, vol.46, pp.1433-1437, 2007.

X. Pei, AAV8 virions hijack serum proteins to increase hepatocyte binding for transduction enhancement, Virology, vol.518, pp.95-102, 2018.

M. Wang, Direct interaction of human serum proteins with AAV virions to enhance AAV transduction: immediate impact on clinical applications, Gene Ther, vol.24, pp.49-59, 2017.

P. Veron, Humoral and cellular capsid-specific immune responses to adeno-associated virus type 1 in randomized healthy donors, J. Immunol, vol.188, pp.6418-6424, 2012.

F. Mingozzi, Overcoming preexisting humoral immunity to AAV using capsid decoys, Sci. Transl. Med, vol.5, 2013.

M. Corti, Evaluation of Readministration of a Recombinant Adeno-Associated Virus Vector Expressing Acid Alpha-Glucosidase in Pompe Disease: Preclinical to Clinical Planning, Hum. Gene Ther. Clin. Dev, vol.26, pp.185-193, 2015.

A. Meliani, Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration, Nat. Commun, vol.9, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02177709

F. Mingozzi, Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue, Gene Ther, vol.20, pp.417-424, 2013.

A. M. Davidoff, Purification of recombinant adeno-associated virus type 8 vectors by ion exchange chromatography generates clinical grade vector stock, J. Virol. Methods, vol.121, pp.209-215, 2004.

G. Qu, Separation of adeno-associated virus type 2 empty particles from genome containing vectors by anion-exchange column chromatography, J. Virol. Methods, vol.140, pp.183-192, 2007.

C. Carrasco, M. Castellanos, P. J. De-pablo, and M. G. Mateu, Manipulation of the mechanical properties of a virus by protein engineering, Proc. Natl Acad. Sci. USA 105, pp.4150-4155, 2008.

G. P. Gao, Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy, Proc. Natl Acad. Sci. USA, vol.99, pp.11854-11859, 2002.

R. Bambauer, R. Latza, D. Burgard, and R. Schiel, Therapeutic Apheresis in Immunologic Renal and Neurological Diseases, Ther. Apher. Dial, vol.21, pp.6-21, 2017.

F. Mingozzi, Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver, Blood, vol.110, pp.2334-2341, 2007.

D. J. Hui, AAV capsid CD8 + T-cell epitopes are highly conserved across AAV serotypes, Mol. Ther. Methods Clin. Dev, vol.2, p.15029, 2015.

F. Mingozzi, CD8(+) T-cell responses to adeno-associated virus capsid in humans, Nat. Med, vol.13, pp.419-422, 2007.

A. Goyenvalle, A. Babbs, G. J. Van-ommen, L. Garcia, and K. E. Davies, Enhanced exon-skipping induced by U7 snRNA carrying a splicing silencer sequence: Promising tool for DMD therapy, Mol. Ther, vol.17, pp.1234-1240, 2009.

T. Virag, S. Cecchini, and R. M. Kotin, Producing recombinant adeno-associated virus in foster cells: overcoming production limitations using a baculovirus-insect cell expression strategy. Hum, Gene Ther, vol.20, pp.807-817, 2009.

E. Ayuso, High AAV vector purity results in serotype-and tissue-independent enhancement of transduction efficiency, Gene Ther, vol.17, pp.503-510, 2010.

A. Meliani, Determination of anti-adeno-associated virus vector neutralizing antibody titer with an in vitro reporter system, Hum. Gene Ther. Methods, 2015.